olaparib
merck,astrazeneca
['brca', 'gyn', 'aml,(-streamline),(-seamless),(-kamloops)', 'mds', 'orzora', 'ovarian']
orzora data of #parpi second line maintenance in #ovariancancer demonstrates consistent survival benefit irrespective of the type of mutation (#brca - germline vs somatic vs other hrrm) more data for #mds #aml - 3.4% incidence in this patient population... #asco22 #gyncsm 
Gyn Onc at MD Anderson. She/Hers. Wife of @DrJasonWestin. Innovative clinical trials. #JCO social media editor. Opinions=mine.
https://t.co/QLXLDKSThc